Abstract
This chapter addresses the more recent discovery of “-omic” putative biomarkers of perinatal asphyxia. The urgent need for more tools to intercept as early as possible the onset of hypoxic and/or ischemic signs of brain damage in a fetus or in a newborn is paramount due to the available treatment by therapeutic hypothermia. The precocious identification of neonates who will benefit from this treatment may help physicians to reduce, if not eliminate, the burden of the disability these human beings will carry on for all their lives. Genomics, proteomics, transcriptomics, and metabolomics promise to be able to unravel the complex network of physiological and pathological alteration caused by the primary hypoxic insult. A more in-depth understanding of these mechanisms will guarantee the identification, validation, and implementation of new diagnostic tests able to obtain an early diagnosis (biomarker of damage) and a more accurate prognosis (biomarker of outcome). This comprehension may also pave the way to new neuroprotective drugs and/or treatment, targeted to inhibit or limit primary and secondary damages activated by the abrupt shortening of available oxygen. Although promising, all the so far published “putative” biomarkers failed in the routine application in the neonatal field mainly due to the temporal gap existing between the onset of hypoxia–ischemia and the first diagnosis, which requests an in-depth clinical evaluation and further instrumental analysis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
R. Antonucci, A. Porcella, M.D. Pilloni, Perinatal asphyxia in the term newborn. J. Pediatr. Neonatal Individualized Med. (JPNIM) 3, e030269 (2014)
E. Locci, A. Noto, M. Puddu, et al., A longitudinal 1H-NMR metabolomics analysis of urine from newborns with hypoxic-ischemic encephalopathy undergoing hypothermia therapy. Clinical and medical legal insights. PLoS One 13, e0194267 (2018)
S.M. Donn, M.L. Chiswick, J.M. Fanaroff, Medico-legal implications of hypoxic-ischemic birth injury. Semin. Fetal Neonatal Med. 19, 317–321 (2014)
S.M. Donn, G.N. McAbee, Medicolegal Issues in Paediatrics, 7th edn. (AAP, Illinois, 2012), pp. 58–59
E.M. Graham, I. Burd, A.D. Everett, et al., Blood biomarkers for evaluation of perinatal encephalopathy. Front. Pharmacol. 7, 196 (2016)
G. McMichael, M.N. Bainbridge, E. Haan, et al., Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy. Mol. Psychiatry 20, 176–182 (2015)
A.H. MacLennan, S. Lewis, A. Moreno-De-Luca, et al., Genetic or other causation should not change the clinical diagnosis of cerebral palsy. J. Child Neurol. 34, 472–476 (2019)
S.C. Jin, S.A. Lewis, S. Bakhtiari, et al., Mutations disrupting neuritogenesis genes confer risk for cerebral palsy. Nat. Genet. 52, 1046–1056 (2020)
S.A. Lewis, S. Shetty, B.A. Wilson, et al., Insights from genetic studies of cerebral palsy. Front. Neurol. 11, 625428 (2021)
K. Rosenkranz, C. May, C. Meier, et al., Proteomic analysis of alterations induced by perinatal hypoxic−ischemic brain injury. J. Proteome Res. 11, 5794–5803 (2012)
Z. Shi, K. Luo, S. Deol, et al., A systematic review of noninflammatory cerebrospinal fluid biomarkers for clinical outcome in neonates with perinatal hypoxic brain injury that could be biologically significant. J. Neurosci. Res. 100, 2154–2173 (2022)
D.P. Bartel, MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009)
D. Motti, J.L. Bixby, V.P. Lemmon, MicroRNAs and neuronal development. Semin. Fetal Neonatal Med. 17, 347–352 (2012)
E.S. Peeples, MicroRNA therapeutic targets in neonatal hypoxic-ischemic brain injury: a narrative review. Pediatr. Res. (2022). https://doi.org/10.1038/s41390-022-02196-4
M. Fabbri, TLRs as miRNA receptors. Cancer Res. 72, 6333–6337 (2012)
B. Ason, D.K. Darnell, B. Wittbrodt, et al., Differences in vertebrate microRNA expression. Proc. Natl. Acad. Sci. U. S. A. 103, 14385–14389 (2006)
M. Kapsimali, W.P. Kloosterman, E. de Bruijn, et al., MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol. 8, R173 (2007)
V. Ponnusamy, P.K. Yip, The role of microRNAs in newborn brain development and hypoxic ischaemic encephalopathy. Neuropharmacology 149, 55–65 (2019)
V. Ponnusamy, O. Kapellou, E. Yip, et al., A study of microRNAs from dried blood spots in newborns after perinatal asphyxia: a simple and feasible biosampling method. Pediatr. Res. 79, 799–805 (2016)
A.M. Looney, C.E. Ahearne, B. Hallberg, et al., Downstream mRNA target analysis in neonatal hypoxic-ischaemic encephalopathy identifies novel marker of severe injury: a proof of concept paper. Mol. Neurobiol. 54, 8420–8428 (2017)
Z. Wang, Y. Liu, M. Shao, et al., Combined prediction of miR-210 and miR-374a for severity and prognosis of hypoxic-ischemic encephalopathy. Brain Behav. 8, e00835 (2017)
C.L. Whitehead, W.T. Teh, S.P. Walker, et al., Circulating MicroRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero. PLoS One 8, e78487 (2013)
H.T. Garberg, M.U. Huun, L.O. Baumbusch, et al., Temporal profile of circulating microRNAs after global hypoxia-ischemia in newborn piglets. Neonatology 111, 133–139 (2017)
A.M. Looney, B.H. Walsh, G. Moloney, et al., Downregulation of umbilical cord blood levels of miR-374a in neonatal hypoxic ischemic encephalopathy. J. Pediatr. 167, 269–73.e2 (2015)
M.P. O’Sullivan, A.M. Looney, G.M. Moloney, et al., Validation of altered umbilical cord blood MicroRNA expression in neonatal hypoxic-ischemic encephalopathy. JAMA Neurol. 76, 333–341 (2019)
E. Locci, M. Stocchero, R. Gottardo, et al., Comparative use of aqueous humour 1H NMR metabolomics and potassium concentration for PMI estimation in an animal model. Int. J. Legal Med. 135, 845–852 (2021)
E. Locci, A. Chighine, A. Noto, et al., Metabolomics improves the histopathological diagnosis of asphyxial deaths: an animal proof-of-concept model. Sci. Rep. 11, 10102 (2021)
E. Locci, G. Bazzano, R. Demontis, et al., Exploring perinatal asphyxia by metabolomics. Meta 10, 141 (2020)
J.D. Piñeiro-Ramos, M.M. Cascant, A. Núñez-Ramiro, et al., Noninvasive monitoring of evolving urinary metabolic patterns in neonatal encephalopathy. Pediatr. Res. 91, 598–605 (2022)
E. Valerio, V. Mardegan, M. Stocchero, et al., Urinary metabotypes of newborns with perinatal asphyxia undergoing therapeutic hypothermia. PLoS One 17, e0273175 (2022)
C. Fattuoni, F. Palmas, A. Noto, et al., Perinatal asphyxia: a review from a metabolomics perspective. Molecules 20, 7000–7016 (2015)
M.J. Debuf, K. Carkeek, F. Piersigilli, A metabolomic approach in search of neurobiomarkers of perinatal asphyxia: a review of the current literature. Front. Pediatr. 9, 674585 (2021)
N.M. Denihan, J.A. Kirwan, B.H. Walsh, et al., Untargeted metabolomic analysis and pathway discovery in perinatal asphyxia and hypoxic-ischaemic encephalopathy. J. Cereb. Blood Flow Metab. 39, 147–162 (2019)
D.S. O’Boyle, W.B. Dunn, D. O’Neill, et al., Improvement in the prediction of neonatal hypoxic-ischemic encephalopathy with the integration of umbilical cord metabolites and current clinical makers. J. Pediatr. 229, 175–181.e1 (2021)
D.M. Murray, Biomarkers in neonatal hypoxic-ischemic encephalopathy - review of the literature to date and future directions for research, in Handbook of Clinical Neurology, ed. by L.S. de Vries, H.C. Glass, (Elsevier, Amsterdam, 2019), pp. 281–293
D.M. Ferriero, S.L. Bonifacio, The search continues for the elusive biomarkers of neonatal brain injury. J. Pediatr. 164, 438–440 (2014)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chighine, A., Fratini, R., d’Aloja, E., Nioi, M. (2024). A Conundrum Waiting for Clinical, Technical, and Medico-Legal Solutions: Looking for the “Perfect Biomarker” of Perinatal Asphyxia. In: Pani, D. (eds) Innovative Technologies and Signal Processing in Perinatal Medicine. Springer, Cham. https://doi.org/10.1007/978-3-031-32625-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-031-32625-7_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-32624-0
Online ISBN: 978-3-031-32625-7
eBook Packages: EngineeringEngineering (R0)